Skip to content

Study · Not a test of the peptide alone · 2025

18 results

Interest in Treatment with GLP-1 Receptor Agonists for the Management of Insufficient Weight Loss or Weight Regain After Bariatric Surgery.

Abdallah H, Klink WH, Derienne J, Voican C, Perlemuter G, Courie R, Dagher I, Tranchart H

Obesity surgery6 Sept 2025Cited by 6 (Europe PMC)

PMID40913138 (opens in a new tab)PMCIDPMC12540538 (opens in a new tab)DOI10.1007/s11695-025-08210-y (opens in a new tab)PepBankPUB-40913138
Download PDFPubMedAsk about this study
Jump to 18 results

Summary

BackgroundBariatric surgery (BS) is the most effective treatment for severe obesity, but a significant proportion of patients experience insufficient weight loss (IWL) or weight regain. Glucagon-like peptide-1 receptor agonists (arGLP-1) have emerged as a promising adjunctive therapy for managing these suboptimal outcomes. This study evaluates the efficacy and safety of arGLP-1 in patients with IWL or WR after BS.MethodsA retrospective analysis was conducted on 100 patients who underwent BS (96 sleeve gastrectomy, 4 gastric bypass) and received arGLP-1 therapy (semaglutide or dulaglutide) for IWL (defined as < 50% excess weight loss (EWL) from baseline), and WR (a ≥ 10 kg increase from the nadir weight post-surgery). Data on weight loss, comorbidities, and adverse events were collected over a median follow-up of 1 year. Statistical analyses included paired t-tests, Wilcoxon signed-rank tests, and chi-squared tests.ResultsAt 1 year, patients achieved significant weight loss with a median total weight loss (%TWL) of 25.5% and a median excess weight loss (%EWL) of 66.3% compared to 16.6% and 40.8%, respectively, at treatment initiation with BMI reduction of 3.7 kg/m2. Significant improvements were observed in comorbidities, including reductions in obstructive sleep apnea (- 30%), hypertension (- 40%), and arthralgia (- 56.5%). Glycated hemoglobin levels decreased by 0.8 points. Treatment was well-tolerated, with nausea being the most common side effect (5% discontinuation rate).ConclusionarGLP-1 are effective and safe for managing IWL or WR after BS, leading to significant weight loss, comorbidity improvement, and sustained %TWL. These findings support their use as a valuable adjunctive obesity management medication (OMMs) in post-bariatric care, though long-term adherence and cost-effectiveness require further investigation.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study18

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone18

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    After bariatric surgery, pooled semaglutide or dulaglutide treatment was linked to total weight loss increasing from 16.6% to 25.5%.

    In plain wordsAfter bariatric surgery, pooled semaglutide or dulaglutide use was linked to increased total weight loss compared with treatment initiation.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseTotal weight loss
    Study

    n = 100

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Median total weight loss (%TWL)
    25.5%
    at 1 year
    Median total weight loss (%TWL)
    16.6%
    at treatment initiation

    Source sentences

    Summary
    At 1 year, patients achieved significant weight loss with a median total weight loss (%TWL) of 25.5% and a median excess weight loss (%EWL) of 66.3% compared to 16.6% and 40.8%, respectively, at treatment initiation with BMI reduction of 3.7 kg/m2.
    2 context sentences
    Summary · context
    A retrospective analysis was conducted on 100 patients who underwent BS (96 sleeve gastrectomy, 4 gastric bypass) and received arGLP-1 therapy (semaglutide or dulaglutide) for IWL (defined as < 50% excess weight loss (EWL) from baseline), and WR (a ≥ 10 kg increase from the nadir weight post-surgery).
    Summary · context
    Data on weight loss, comorbidities, and adverse events were collected over a median follow-up of 1 year.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 02HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    After bariatric surgery, pooled semaglutide or dulaglutide treatment was linked to total weight loss increasing from 16.6% to 25.5%.

    In plain wordsAfter bariatric surgery, pooled semaglutide or dulaglutide use was linked to increased total weight loss compared with treatment initiation.

    Peptide
    Semaglutide
    Outcome
    IncreaseTotal weight loss
    Study

    n = 100

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Median total weight loss (%TWL)
    25.5%
    at 1 year
    Median total weight loss (%TWL)
    16.6%
    at treatment initiation

    Source sentences

    Summary
    At 1 year, patients achieved significant weight loss with a median total weight loss (%TWL) of 25.5% and a median excess weight loss (%EWL) of 66.3% compared to 16.6% and 40.8%, respectively, at treatment initiation with BMI reduction of 3.7 kg/m2.
    2 context sentences
    Summary · context
    A retrospective analysis was conducted on 100 patients who underwent BS (96 sleeve gastrectomy, 4 gastric bypass) and received arGLP-1 therapy (semaglutide or dulaglutide) for IWL (defined as < 50% excess weight loss (EWL) from baseline), and WR (a ≥ 10 kg increase from the nadir weight post-surgery).
    Summary · context
    Data on weight loss, comorbidities, and adverse events were collected over a median follow-up of 1 year.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 03HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    After bariatric surgery, pooled semaglutide or dulaglutide treatment was linked to excess weight loss increasing from 40.8% to 66.3%.

    In plain wordsAfter bariatric surgery, pooled semaglutide or dulaglutide use was linked to increased excess weight loss compared with treatment initiation.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseExcess weight loss
    Study

    n = 100

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Median excess weight loss (%EWL)
    66.3%
    at 1 year
    Median excess weight loss (%EWL)
    40.8%
    at treatment initiation

    Source sentences

    Summary
    At 1 year, patients achieved significant weight loss with a median total weight loss (%TWL) of 25.5% and a median excess weight loss (%EWL) of 66.3% compared to 16.6% and 40.8%, respectively, at treatment initiation with BMI reduction of 3.7 kg/m2.
    2 context sentences
    Summary · context
    A retrospective analysis was conducted on 100 patients who underwent BS (96 sleeve gastrectomy, 4 gastric bypass) and received arGLP-1 therapy (semaglutide or dulaglutide) for IWL (defined as < 50% excess weight loss (EWL) from baseline), and WR (a ≥ 10 kg increase from the nadir weight post-surgery).
    Summary · context
    Data on weight loss, comorbidities, and adverse events were collected over a median follow-up of 1 year.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  4. 04HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    After bariatric surgery, pooled semaglutide or dulaglutide treatment was linked to excess weight loss increasing from 40.8% to 66.3%.

    In plain wordsAfter bariatric surgery, pooled semaglutide or dulaglutide use was linked to increased excess weight loss compared with treatment initiation.

    Peptide
    Semaglutide
    Outcome
    IncreaseExcess weight loss
    Study

    n = 100

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Median excess weight loss (%EWL)
    66.3%
    at 1 year
    Median excess weight loss (%EWL)
    40.8%
    at treatment initiation

    Source sentences

    Summary
    At 1 year, patients achieved significant weight loss with a median total weight loss (%TWL) of 25.5% and a median excess weight loss (%EWL) of 66.3% compared to 16.6% and 40.8%, respectively, at treatment initiation with BMI reduction of 3.7 kg/m2.
    2 context sentences
    Summary · context
    A retrospective analysis was conducted on 100 patients who underwent BS (96 sleeve gastrectomy, 4 gastric bypass) and received arGLP-1 therapy (semaglutide or dulaglutide) for IWL (defined as < 50% excess weight loss (EWL) from baseline), and WR (a ≥ 10 kg increase from the nadir weight post-surgery).
    Summary · context
    Data on weight loss, comorbidities, and adverse events were collected over a median follow-up of 1 year.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  5. 05HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    After bariatric surgery, pooled semaglutide or dulaglutide treatment was linked to a BMI reduction of 3.7 kg/m².

    In plain wordsAfter bariatric surgery, pooled semaglutide or dulaglutide use was linked to lower BMI than at treatment initiation.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseBMI reduction
    Study

    n = 100

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    BMI reduction
    3.7 kg/m²
    at 1 year

    Source sentences

    Summary
    At 1 year, patients achieved significant weight loss with a median total weight loss (%TWL) of 25.5% and a median excess weight loss (%EWL) of 66.3% compared to 16.6% and 40.8%, respectively, at treatment initiation with BMI reduction of 3.7 kg/m2.
    2 context sentences
    Summary · context
    A retrospective analysis was conducted on 100 patients who underwent BS (96 sleeve gastrectomy, 4 gastric bypass) and received arGLP-1 therapy (semaglutide or dulaglutide) for IWL (defined as < 50% excess weight loss (EWL) from baseline), and WR (a ≥ 10 kg increase from the nadir weight post-surgery).
    Summary · context
    Data on weight loss, comorbidities, and adverse events were collected over a median follow-up of 1 year.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  6. 06HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    After bariatric surgery, pooled semaglutide or dulaglutide treatment was linked to a BMI reduction of 3.7 kg/m².

    In plain wordsAfter bariatric surgery, pooled semaglutide or dulaglutide use was linked to lower BMI than at treatment initiation.

    Peptide
    Semaglutide
    Outcome
    DecreaseBMI reduction
    Study

    n = 100

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    BMI reduction
    3.7 kg/m²
    at 1 year

    Source sentences

    Summary
    At 1 year, patients achieved significant weight loss with a median total weight loss (%TWL) of 25.5% and a median excess weight loss (%EWL) of 66.3% compared to 16.6% and 40.8%, respectively, at treatment initiation with BMI reduction of 3.7 kg/m2.
    2 context sentences
    Summary · context
    A retrospective analysis was conducted on 100 patients who underwent BS (96 sleeve gastrectomy, 4 gastric bypass) and received arGLP-1 therapy (semaglutide or dulaglutide) for IWL (defined as < 50% excess weight loss (EWL) from baseline), and WR (a ≥ 10 kg increase from the nadir weight post-surgery).
    Summary · context
    Data on weight loss, comorbidities, and adverse events were collected over a median follow-up of 1 year.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  7. 07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome

    After bariatric surgery, nausea was the most common side effect during pooled semaglutide or dulaglutide treatment.

    In plain wordsAfter bariatric surgery, nausea was the most common side effect during pooled semaglutide or dulaglutide use.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Direction not reportedNausea
    Study

    n = 100

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Treatment was well-tolerated, with nausea being the most common side effect (5% discontinuation rate).
    2 context sentences
    Summary · context
    A retrospective analysis was conducted on 100 patients who underwent BS (96 sleeve gastrectomy, 4 gastric bypass) and received arGLP-1 therapy (semaglutide or dulaglutide) for IWL (defined as < 50% excess weight loss (EWL) from baseline), and WR (a ≥ 10 kg increase from the nadir weight post-surgery).
    Summary · context
    Data on weight loss, comorbidities, and adverse events were collected over a median follow-up of 1 year.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  8. 08HumanNot a test of Semaglutide aloneObservational studySafety outcome

    After bariatric surgery, nausea was the most common side effect during pooled semaglutide or dulaglutide treatment.

    In plain wordsAfter bariatric surgery, nausea was the most common side effect during pooled semaglutide or dulaglutide use.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedNausea
    Study

    n = 100

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Treatment was well-tolerated, with nausea being the most common side effect (5% discontinuation rate).
    2 context sentences
    Summary · context
    A retrospective analysis was conducted on 100 patients who underwent BS (96 sleeve gastrectomy, 4 gastric bypass) and received arGLP-1 therapy (semaglutide or dulaglutide) for IWL (defined as < 50% excess weight loss (EWL) from baseline), and WR (a ≥ 10 kg increase from the nadir weight post-surgery).
    Summary · context
    Data on weight loss, comorbidities, and adverse events were collected over a median follow-up of 1 year.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  9. 09HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome

    After bariatric surgery, pooled semaglutide or dulaglutide treatment had a 5% discontinuation rate.

    In plain wordsAfter bariatric surgery, 5% of patients discontinued pooled semaglutide or dulaglutide treatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Direction not reportedDiscontinuation
    Study

    n = 100

    Outcome group
    Adverse events · Whole body

    Measurements

    Discontinuation rate
    5%
    treatment discontinuation, after bariatric surgery, pooled semaglutide or dulaglutide

    Source sentences

    Summary
    Treatment was well-tolerated, with nausea being the most common side effect (5% discontinuation rate).
    2 context sentences
    Summary · context
    A retrospective analysis was conducted on 100 patients who underwent BS (96 sleeve gastrectomy, 4 gastric bypass) and received arGLP-1 therapy (semaglutide or dulaglutide) for IWL (defined as < 50% excess weight loss (EWL) from baseline), and WR (a ≥ 10 kg increase from the nadir weight post-surgery).
    Summary · context
    Data on weight loss, comorbidities, and adverse events were collected over a median follow-up of 1 year.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  10. 10HumanNot a test of Semaglutide aloneObservational studySafety outcome

    After bariatric surgery, pooled semaglutide or dulaglutide treatment had a 5% discontinuation rate.

    In plain wordsAfter bariatric surgery, 5% of patients discontinued pooled semaglutide or dulaglutide treatment.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedDiscontinuation
    Study

    n = 100

    Outcome group
    Adverse events · Whole body

    Measurements

    Discontinuation rate
    5%
    treatment discontinuation, after bariatric surgery, pooled semaglutide or dulaglutide

    Source sentences

    Summary
    Treatment was well-tolerated, with nausea being the most common side effect (5% discontinuation rate).
    2 context sentences
    Summary · context
    A retrospective analysis was conducted on 100 patients who underwent BS (96 sleeve gastrectomy, 4 gastric bypass) and received arGLP-1 therapy (semaglutide or dulaglutide) for IWL (defined as < 50% excess weight loss (EWL) from baseline), and WR (a ≥ 10 kg increase from the nadir weight post-surgery).
    Summary · context
    Data on weight loss, comorbidities, and adverse events were collected over a median follow-up of 1 year.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  11. 11HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    After bariatric surgery, pooled semaglutide or dulaglutide use was linked to a 30% reduction in obstructive sleep apnea.

    In plain wordsAfter bariatric surgery, pooled semaglutide or dulaglutide use was linked to less obstructive sleep apnea.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseObstructive sleep apnea
    Study

    n: not reported in source

    Outcome group
    Sleep · Respiratory

    Measurements

    Change in obstructive sleep apnea
    −30%
    after arGLP-1 therapy

    Source sentences

    Summary
    Significant improvements were observed in comorbidities, including reductions in obstructive sleep apnea (- 30%), hypertension (- 40%), and arthralgia (- 56.5%).
    2 context sentences
    Summary · context
    A retrospective analysis was conducted on 100 patients who underwent BS (96 sleeve gastrectomy, 4 gastric bypass) and received arGLP-1 therapy (semaglutide or dulaglutide) for IWL (defined as < 50% excess weight loss (EWL) from baseline), and WR (a ≥ 10 kg increase from the nadir weight post-surgery).
    Summary · context
    Data on weight loss, comorbidities, and adverse events were collected over a median follow-up of 1 year.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  12. 12HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    After bariatric surgery, pooled semaglutide or dulaglutide use was linked to a 30% reduction in obstructive sleep apnea.

    In plain wordsAfter bariatric surgery, pooled semaglutide or dulaglutide use was linked to less obstructive sleep apnea.

    Peptide
    Semaglutide
    Outcome
    DecreaseObstructive sleep apnea
    Study

    n: not reported in source

    Outcome group
    Sleep · Respiratory

    Measurements

    Change in obstructive sleep apnea
    −30%
    after arGLP-1 therapy

    Source sentences

    Summary
    Significant improvements were observed in comorbidities, including reductions in obstructive sleep apnea (- 30%), hypertension (- 40%), and arthralgia (- 56.5%).
    2 context sentences
    Summary · context
    A retrospective analysis was conducted on 100 patients who underwent BS (96 sleeve gastrectomy, 4 gastric bypass) and received arGLP-1 therapy (semaglutide or dulaglutide) for IWL (defined as < 50% excess weight loss (EWL) from baseline), and WR (a ≥ 10 kg increase from the nadir weight post-surgery).
    Summary · context
    Data on weight loss, comorbidities, and adverse events were collected over a median follow-up of 1 year.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  13. 13HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    After bariatric surgery, pooled semaglutide or dulaglutide use was linked to a 40% reduction in hypertension.

    In plain wordsAfter bariatric surgery, pooled semaglutide or dulaglutide use was linked to less hypertension.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHypertension
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular

    Measurements

    Change in hypertension
    −40%
    after arGLP-1 therapy

    Source sentences

    Summary
    Significant improvements were observed in comorbidities, including reductions in obstructive sleep apnea (- 30%), hypertension (- 40%), and arthralgia (- 56.5%).
    2 context sentences
    Summary · context
    A retrospective analysis was conducted on 100 patients who underwent BS (96 sleeve gastrectomy, 4 gastric bypass) and received arGLP-1 therapy (semaglutide or dulaglutide) for IWL (defined as < 50% excess weight loss (EWL) from baseline), and WR (a ≥ 10 kg increase from the nadir weight post-surgery).
    Summary · context
    Data on weight loss, comorbidities, and adverse events were collected over a median follow-up of 1 year.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  14. 14HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    After bariatric surgery, pooled semaglutide or dulaglutide use was linked to a 40% reduction in hypertension.

    In plain wordsAfter bariatric surgery, pooled semaglutide or dulaglutide use was linked to less hypertension.

    Peptide
    Semaglutide
    Outcome
    DecreaseHypertension
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular

    Measurements

    Hypertension change
    −40%
    hypertension, after bariatric surgery, pooled semaglutide or dulaglutide

    Source sentences

    Summary
    Significant improvements were observed in comorbidities, including reductions in obstructive sleep apnea (- 30%), hypertension (- 40%), and arthralgia (- 56.5%).
    2 context sentences
    Summary · context
    A retrospective analysis was conducted on 100 patients who underwent BS (96 sleeve gastrectomy, 4 gastric bypass) and received arGLP-1 therapy (semaglutide or dulaglutide) for IWL (defined as < 50% excess weight loss (EWL) from baseline), and WR (a ≥ 10 kg increase from the nadir weight post-surgery).
    Summary · context
    Data on weight loss, comorbidities, and adverse events were collected over a median follow-up of 1 year.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  15. 15HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    After bariatric surgery, pooled semaglutide or dulaglutide use was linked to a 56.5% reduction in arthralgia.

    In plain wordsAfter bariatric surgery, pooled semaglutide or dulaglutide use was linked to less joint pain.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseArthralgia
    Study

    n: not reported in source

    Outcome group
    Pain · Musculoskeletal

    Measurements

    Arthralgia change
    −56.5%
    arthralgia, after bariatric surgery, pooled semaglutide or dulaglutide

    Source sentences

    Summary
    Significant improvements were observed in comorbidities, including reductions in obstructive sleep apnea (- 30%), hypertension (- 40%), and arthralgia (- 56.5%).
    2 context sentences
    Summary · context
    A retrospective analysis was conducted on 100 patients who underwent BS (96 sleeve gastrectomy, 4 gastric bypass) and received arGLP-1 therapy (semaglutide or dulaglutide) for IWL (defined as < 50% excess weight loss (EWL) from baseline), and WR (a ≥ 10 kg increase from the nadir weight post-surgery).
    Summary · context
    Data on weight loss, comorbidities, and adverse events were collected over a median follow-up of 1 year.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  16. 16HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    After bariatric surgery, pooled semaglutide or dulaglutide use was linked to a 56.5% reduction in arthralgia.

    In plain wordsAfter bariatric surgery, pooled semaglutide or dulaglutide use was linked to less joint pain.

    Peptide
    Semaglutide
    Outcome
    DecreaseArthralgia
    Study

    n: not reported in source

    Outcome group
    Pain · Musculoskeletal

    Measurements

    Arthralgia change
    −56.5%
    arthralgia, after bariatric surgery, pooled semaglutide or dulaglutide

    Source sentences

    Summary
    Significant improvements were observed in comorbidities, including reductions in obstructive sleep apnea (- 30%), hypertension (- 40%), and arthralgia (- 56.5%).
    2 context sentences
    Summary · context
    A retrospective analysis was conducted on 100 patients who underwent BS (96 sleeve gastrectomy, 4 gastric bypass) and received arGLP-1 therapy (semaglutide or dulaglutide) for IWL (defined as < 50% excess weight loss (EWL) from baseline), and WR (a ≥ 10 kg increase from the nadir weight post-surgery).
    Summary · context
    Data on weight loss, comorbidities, and adverse events were collected over a median follow-up of 1 year.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  17. 17HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    After bariatric surgery, pooled semaglutide or dulaglutide use was linked to glycated hemoglobin decreasing by 0.8 points.

    In plain wordsAfter bariatric surgery, pooled semaglutide or dulaglutide use was linked to lower long-term blood sugar.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseGlycated hemoglobin
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Glycated hemoglobin change
    −0.8 points
    HbA1c, after bariatric surgery, pooled semaglutide or dulaglutide

    Source sentences

    Summary
    Glycated hemoglobin levels decreased by 0.8 points.
    2 context sentences
    Summary · context
    A retrospective analysis was conducted on 100 patients who underwent BS (96 sleeve gastrectomy, 4 gastric bypass) and received arGLP-1 therapy (semaglutide or dulaglutide) for IWL (defined as < 50% excess weight loss (EWL) from baseline), and WR (a ≥ 10 kg increase from the nadir weight post-surgery).
    Summary · context
    Data on weight loss, comorbidities, and adverse events were collected over a median follow-up of 1 year.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  18. 18HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    After bariatric surgery, pooled semaglutide or dulaglutide use was linked to glycated hemoglobin decreasing by 0.8 points.

    In plain wordsAfter bariatric surgery, pooled semaglutide or dulaglutide use was linked to lower long-term blood sugar.

    Peptide
    Semaglutide
    Outcome
    DecreaseGlycated hemoglobin
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Glycated hemoglobin change
    −0.8 points
    HbA1c, after bariatric surgery, pooled semaglutide or dulaglutide

    Source sentences

    Summary
    Glycated hemoglobin levels decreased by 0.8 points.
    2 context sentences
    Summary · context
    A retrospective analysis was conducted on 100 patients who underwent BS (96 sleeve gastrectomy, 4 gastric bypass) and received arGLP-1 therapy (semaglutide or dulaglutide) for IWL (defined as < 50% excess weight loss (EWL) from baseline), and WR (a ≥ 10 kg increase from the nadir weight post-surgery).
    Summary · context
    Data on weight loss, comorbidities, and adverse events were collected over a median follow-up of 1 year.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.